Rate of Thromboembolic Events in Mesothelioma

Annals of Thoracic Surgery

Volumn 85, Issue 3, 2008, Pages 1032-1038

  Nguyen, Derrick ^a   Lee, Sang Joon ^a   Libby, Edward ^a   Verschraegen, Claire ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTERY EMBOLISM; ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOEMBOLISM; TUMOR LOCALIZATION;

ADULT; AGED; FEMALE; HEART NEOPLASMS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERICARDIUM; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 39149113434     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.11.064     Document Type: Article

References (37)

1. Munoz A., Barcelo R., and Lopez-Vivanco G. Malignant mesothelioma. N Engl J Med 354 (2006) 305-307
2. Antman K.H. Natural history and epidemiology of malignant mesothelioma. Chest 103 4 Suppl (1993) 373S-376S
3. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
4. Lee A.Y., and Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 107 23 Suppl 1 (2003) I-17-I-21
5. Heit J.A. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3 (2005) 1611-1617
6. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
7. Green R., and Ouriel K. Venous and lymphatic disease. In: Schwartz S.I. (Ed). Principles of Surgery. 7th ed. (1999), McGraw Hill, New York 1005-1032
8. López J.A., Kearon C., and Lee A.Y. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program (2004) 439-456
9. Murchison J.T., Wylie L., and Stockton D.L. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 91 (2004) 92-95
10. Blom J.W., Vanderschoot J.P., Oostindier M.J., et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4 (2006) 529-535
11. Kakkar A.K., Levine M., Pinedo H.M., et al. Venous thrombosis in cancer patients: insights from the Frontline survey. Oncologist 8 (2003) 381-388
12. Sorensen H.T., Mellemkjaer L., Olsen J.H., and Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
13. Idell S., Pueblitz S., Emri S., et al. Regulation of fibrin deposition by malignant mesothelioma. Am J Pathol 147 (1995) 1318-1329
14. Nakano T., Chahinian A.P., Shinjo M., et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 77 (1998) 907-912
15. Klerk C.P., Smorenburg S.M., Otten H.M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135
16. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 (2004) 1944-1948
17. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
18. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., et al. Do heparins do more than just treat thrombosis?. The influence of heparins on cancer spread. Thromb Haemost 82 (1999) 947-952
19. Curran D., Sahmoud T., Therasse P., et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 (1998) 145-152
20. Herndon J.E., Green M.R., Chahinian A.P., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
21. Verschraegen C., Key C., and Hassan R. Clinical presentation and natural history of mesothelioma: abdominal. In: Pass H.I., Vogelzang N., and Carbone M. (Eds). Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies (2005), Springer, New York 391-401
22. Steele J.P. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 19 (2005) 1041-1052 vi
23. Schafer A.I. Hypercoagulable states: molecular genetics to clinical practice. Lancet 344 (1994) 1739-1742
24. Adess M., Eisner R., Nand S., et al. Thromboembolism in cancer patients: pathogenesis and treatment. Clin Appl Thromb Hemost 12 (2006) 254-266
25. Lwaleed B.A., Cooper A.J., Voegeli D., and Getliffe K. Tissue factor: a critical role in inflammation and cancer. Biol Res Nurs 9 (2007) 97-107
26. Molnar S., Guglielmone H., and Lavarda M. Procoagulant factors in patients with cancer. Hematology (2007) 1 (epub)
27. VanDeWater L., Tracy P.B., Aronson D., et al. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 45 (1985) 5521-5525
28. Medina C., Jurasz P., Santos-Martinez M.J., et al. Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp Ther 317 (2006) 739-745
29. Matsui H., Nishinaka K., Oda M., et al. Trousseau syndrome due to pleural mesothelioma. Neurologist 13 (2007) 205-208
30. Kumar P., and Kratzke R.A. Molecular prognostic markers in malignant mesothelioma. Lung Cancer 49 Suppl 1 (2005) S53-S60
31. Robinson B.W., Creaney J., Lake R., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362 (2003) 1612-1616
32. Pass H.I., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353 (2005) 1564-1573
33. Pass H.I., Liu Z., Wali A., et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10 (2004) 849-859
34. Senger D.R., Perruzzi C.A., Papadopoulos-Sergiou A., and Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 5 (1994) 565-574
35. Hull R.D., Pineo G.F., Mah A.F., Brant R.F., and LITE Investigators. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. J Thromb Haemost 1 Suppl 1 (2003) OC395
36. Lee A.Y., Rickles F.R., Julian J.A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
37. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271